Therapeutic Antibody‐Based Drugs in the Treatment of Human Inflammatory Disorders

Sedger, LM; Ranasinghe, C; McDermott, MF; Asvadi, P

Therapeutic Antibody‐Based Drugs in the Treatment of Human Inflammatory Disorders

Sedger, LM

Ranasinghe, C McDermott, MF Asvadi, P

Permalink

Publisher:: In Tech
Publication Type:: Chapter
Citation:: "Immunotherapy - Myths, Reality, Ideas, Future", book edited by Krassimir Metodiev, ISBN 978-953-51-3106-9, Print ISBN 978-953-51-3105-2, 2017, pp. 223 - 270
Issue Date:: 2017-04-26

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.93 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Sedger, LM https://orcid.org/0000-0003-1009-5683	en_US
dc.contributor.author	Ranasinghe, C	en_US
dc.contributor.author	McDermott, MF	en_US
dc.contributor.author	Asvadi, P	en_US
dc.contributor.editor	Metodiev, K	en_US
dc.date.issued	2017-04-26	en_US
dc.identifier.citation	"Immunotherapy - Myths, Reality, Ideas, Future", book edited by Krassimir Metodiev, ISBN 978-953-51-3106-9, Print ISBN 978-953-51-3105-2, 2017, pp. 223 - 270	en_US
dc.identifier.isbn	978-953-51-3106-9	en_US
dc.identifier.uri	http://hdl.handle.net/10453/123151
dc.description.abstract	Abstract. Inflammation causes debilitating human conditions and older treatments rely on global immunosuppression that non‐specifically alleviates symptoms. Currently, several monoclonal antibodies (mAbs) are available that specifically block pro‐inflammatory cytokines. These include mAbs specific to tumour necrosis factor (TNF), interleukin (IL)‐1β, IL‐6, IL‐17 and IL‐12/IL‐23. The chapter summarises the key elements in human inflammatory disease conditions, including various forms of arthritis, psoriasis, Crohn's disease and ulcerative colitis, plus pyrin‐associated inflammatory syndromes and periodic fevers, to explain the benefit of cytokine neutralisation through mAb‐type reagents. The chapter reviews the efficacy and safety of the current repertoire of anti‐cytokine/cytokine receptor mAbs. It also discusses the known side effects and adverse events that are sometimes associated with systemic blockade of cytokines in vivo, and concludes that the accumulating knowledge of treatment failures can reveal unappreciated aspects of cytokine biology and even new treatment opportunities. The chapter includes mention of the rapidly expanding cohort of biosimilar mAbs and the mAbs to IL‐4, IL‐5 and IL‐13 that are now emerging, in addition to the need for treatments for disorders that remain refractory to the current repertoire of anti‐cytokine mAbs and conventional treatments. Thus, here we summarise the current status of anti‐cytokine mAbs for human inflammatory diseases.	en_US
dc.publisher	In Tech	en_US
dc.relation.ispartof	"Immunotherapy - Myths, Reality, Ideas, Future", book edited by Krassimir Metodiev, ISBN 978-953-51-3106-9, Print ISBN 978-953-51-3105-2	en_US
dc.relation.isbasedon	10.5772/63291	en_US
dc.title	Therapeutic Antibody‐Based Drugs in the Treatment of Human Inflammatory Disorders	en_US
dc.type	Chapter
utslib.location	Croatia	en_US
utslib.for	110703 Autoimmunity	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Medical and Molecular Sciences
utslib.copyright.status	open_access
pubs.consider-herdc	true	en_US
pubs.place-of-publication	Croatia	en_US
pubs.publication-status	Published	en_US

Abstract:

Abstract. Inflammation causes debilitating human conditions and older treatments rely on global immunosuppression that non‐specifically alleviates symptoms. Currently, several monoclonal antibodies (mAbs) are available that specifically block pro‐inflammatory cytokines. These include mAbs specific to tumour necrosis factor (TNF), interleukin (IL)‐1β, IL‐6, IL‐17 and IL‐12/IL‐23. The chapter summarises the key elements in human inflammatory disease conditions, including various forms of arthritis, psoriasis, Crohn's disease and ulcerative colitis, plus pyrin‐associated inflammatory syndromes and periodic fevers, to explain the benefit of cytokine neutralisation through mAb‐type reagents. The chapter reviews the efficacy and safety of the current repertoire of anti‐cytokine/cytokine receptor mAbs. It also discusses the known side effects and adverse events that are sometimes associated with systemic blockade of cytokines in vivo, and concludes that the accumulating knowledge of treatment failures can reveal unappreciated aspects of cytokine biology and even new treatment opportunities. The chapter includes mention of the rapidly expanding cohort of biosimilar mAbs and the mAbs to IL‐4, IL‐5 and IL‐13 that are now emerging, in addition to the need for treatments for disorders that remain refractory to the current repertoire of anti‐cytokine mAbs and conventional treatments. Thus, here we summarise the current status of anti‐cytokine mAbs for human inflammatory diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/123151